Congress logo
Back to Conference page

UICC World Cancer Congress 2006

Bridging the Gap: Transforming Knowledge into Action

July 8-12, 2006, Washington, DC, USA



Sunday, 9 July 2006 - 12:00 PM
9-38

Influence of occult hepatitis B virus infection on hepatocarcinogenesis in patients with chronic hepatitis C virus associated-liver injury: prospective study

Mikako Obika, MD1, Shin-ichi Fujioka, MD1, Toshiyuki Shinji, MD1, Aye Aye Lwin, MD1, Hidenori Shiraha, MD2, Norio Koide, MD1, and Yasushi Shiratori, MD2. (1) Laboratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama-city, 700-8558, Japan, (2) Gastroenterology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama-city, 700-8558, Japan

Objective:Occult hepatitis B virus (HBV) infection is defined by presence of HBV DNA in the serum or liver in persons lacking hepatitis B surface antigen (HBsAg) in the serum. A high prevalence of occult HBV has been reported in hepatocellular carcinoma (HCC). We have already reported that the presence of the HBV-DNA in patients with chronic hepatitis C virus (HCV) associated-liver injury appears to promote hepatocarcinogenesis from a retrospective study. To confirm this notion, we performed a prospective study on patients with chronic HCV associated-liver injury whether HBV occult infection can promote the development of HCC.

Methods:173 patients with chronic HCV associated-liver injury without HBsAg were studied. Most of them received interferon (IFN) therapy. Liver biopsies were taken from 1997 to 2003 under informed consent. HBV-DNA was determined by the real-time polymerase chain reaction (PCR) method.

Results:Of 173 patients, HBV-DNA was detected in 9 patients (5.2%). At the present time, we could follow 118 patients and 7 patients were HBV-DNA positive (5.9%), 10 patients developed HCC (8.5%). 2 of 10 HCC patients were HBV-DNA positive (HBV positive rate was 20.0%). 8 of 111 HBV-DNA negative patients developed HCC (7.2%), whereas 2 of 7 HBV-DNA positive patients developed HCC (28.6%). Regarding to the response to IFN therapy, Sustained Virological Response (SVR) was obtained in 39% of the HBV-DNA negative patients and in 25% of the HBV-DNA positive patients.


See more of Cancer Research, Detection and Treatment
See more of Cancer Research, Detection and Treatment

See more of The UICC World Cancer Congress 2006